Vancomycin dosing: Assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software

Annals of Pharmacotherapy

Volumn 45, Issue 6, 2011, Pages 757-763

  Nunn, Maya O ^a   Corallo, Carmela E ^b   Aubron, Cecile ^c   Poole, Susan ^c   Dooley, Michael J ^c   Cheng, Allen C ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Alfred Health ^*  (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Pharmacokinetic modeling; Therapeutic drug monitoring; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

ADULT; AGED; ARTICLE; BODY MASS; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CONCENTRATION; DRUG DOSE; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBESITY; PATIENT INFORMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SOFTWARE; TIME FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 79958821290     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P634     Document Type: Article

References (29)

1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51.
2. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6.
3. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182 e1-7.
4. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
5. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(suppl 2):S4-9.
6. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42.
7. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
8. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55.
9. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
10. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7.
11. Helgason KO, Thomson AH, Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008;61:1398-9.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
13. Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990;34: 1165-71.
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
15. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
16. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
17. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42(suppl 1):S3-4.
18. Colares VS, Oliveira RB, Abdulkader RC. Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol Dial Transplant 2006;21:3608.
19. Mackett RL, Guay DR. Vancomycin-induced neutropenia. Can Med Assoc J 1985;132:39-40.
20. Mordenti J, Ries C, Brooks GF, Unadkat N, Tseng A. Vancomycin-induced neutropenia complicating bone marrow recovery in a patient with leukaemia. Am J Med 1986;80:333-5.
21. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. 13th ed. Melbourne: Therapeutic Guidelines Ltd., 2006.
22. Fernandez de Gatta Mdel M, Santos Buelga D, Sanchez Navarro A, Dominguez-Gil A, Garcia MJ. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009;48:273-80.
23. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. 14th ed. Melbourne: Therapeutic Guidelines Ltd., 2010.
24. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16:513-8.
25. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987;31:393-7.
26. Hiraki Y, Onga T, Mizoguchi A, Tsuji Y. Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis. J Clin Pharm Ther 2010;35:527-32.
27. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Monit 1989;11:450-4.
28. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006; 31:447-54.
29. Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther 2009;34:473-83.